Oncolytic rhabdovirus
First Claim
Patent Images
1. An attenuated rhabdovirus comprising:
- an M protein having an amino acid sequence that is at least 85% identical to the amino acid sequence of SEQ ID NO;
4 and a tryptophan at the position corresponding to position 123 of SEQ ID NO;
4, orboth a G protein having an amino acid sequence that is at least 80% identical to the amino acid sequence of SEQ ID NO;
5 and an arginine at the position corresponding to position 242 of SEQ ID NO;
5 and an M protein having an amino acid sequence that is at least 80% identical to the amino acid sequence of SEQ ID NO;
4 and a tryptophan at the position corresponding to position 123 of SEQ ID NO;
4.
4 Assignments
0 Petitions
Accused Products
Abstract
Embodiments of the invention include compositions and methods related to Maraba virus and their use as anti-cancer therapeutics. Such rhabdoviruses possess tumor cell killing properties in vitro and in vivo.
118 Citations
32 Claims
-
1. An attenuated rhabdovirus comprising:
-
an M protein having an amino acid sequence that is at least 85% identical to the amino acid sequence of SEQ ID NO;
4 and a tryptophan at the position corresponding to position 123 of SEQ ID NO;
4, orboth a G protein having an amino acid sequence that is at least 80% identical to the amino acid sequence of SEQ ID NO;
5 and an arginine at the position corresponding to position 242 of SEQ ID NO;
5 and an M protein having an amino acid sequence that is at least 80% identical to the amino acid sequence of SEQ ID NO;
4 and a tryptophan at the position corresponding to position 123 of SEQ ID NO;
4. - View Dependent Claims (29)
-
-
2. A method of killing a hyperproliferative cell comprising contacting the cell with an isolated oncolytic rhabdovirus encoding:
-
an M protein having an amino acid sequence that is at least 80% identical to the amino acid sequence of SEQ ID NO;
4 and a tryptophan at the position corresponding to position 123 of SEQ ID NO;
4, orboth a G protein having an amino acid sequence that is at least 80% identical to the amino acid sequence of SEQ ID NO;
5 and an arginine at the position corresponding to position 242 of SEQ ID NO;
5 and an M protein having an amino acid sequence that is at least 80% identical to the amino acid sequence of SEQ ID NO;
4 and a tryptophan at the position corresponding to position 123 of SEQ ID NO;
4. - View Dependent Claims (3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 30)
-
-
13. A method for treating a cancer patient comprising administering an effective amount of an isolated oncolytic rhabdovirus encoding:
-
an M protein having an amino acid sequence that is at least 80% identical to the amino acid sequence of SEQ ID NO;
4 and a tryptophan at the position corresponding to position 123 of SEQ ID NO;
4, orboth a G protein having an amino acid sequence that is at least 80% identical to the amino acid sequence of SEQ ID NO;
5 and an arginine at the position corresponding to position 242 of SEQ ID NO;
5 and an M protein having an amino acid sequence that is at least 80% identical to the amino acid sequence of SEQ ID NO;
4 and a tryptophan at the position corresponding to position 123 of SEQ ID NO;
4. - View Dependent Claims (14, 15, 16, 17, 18, 19, 20, 31)
-
-
21. A composition comprising an isolated oncolytic rhabdovirus having a nucleic acid segment encoding:
-
an M protein having an amino acid sequence that is at least 85% identical to the amino acid sequence of SEQ ID NO;
4 and a tryptophan at the position corresponding to position 123 of SEQ ID NO;
4, orboth a G protein having an amino acid sequence that is at least 80% identical to the amino acid sequence of SEQ ID NO;
5 and an arginine at the position corresponding to position 242 of SEQ ID NO;
5 and an M protein having an amino acid sequence that is at least 80% identical to the amino acid sequence of SEQ ID NO;
4 and a tryptophan at the position corresponding to position 123 of SEQ ID NO;
4. - View Dependent Claims (22, 23, 24, 25, 26, 27, 28, 32)
-
Specification